Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza

Summary Reasons for performing study: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Equine veterinary journal 2013-03, Vol.45 (2), p.235-239
Hauptverfasser: EL-HAGE, C. M., SAVAGE, C. J., MINKE, J. M., FICORILLI, N. P., WATSON, J., GILKERSON, J. R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 239
container_issue 2
container_start_page 235
container_title Equine veterinary journal
container_volume 45
creator EL-HAGE, C. M.
SAVAGE, C. J.
MINKE, J. M.
FICORILLI, N. P.
WATSON, J.
GILKERSON, J. R.
description Summary Reasons for performing study: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data. This study determined the level and duration of humoral immunity following administration of a recombinant canarypox‐vectored vaccine (ALVAC‐EIV) with a primary intervaccination interval of 14 days and booster at 105 days. Objectives: To examine whether protective levels of immunity of adequate duration were achieved following a primary course reduced from a minimum interval of 28 to 14 days. Antibody responses to 2 H3N8 American lineage virus strains (including A/equine/Sydney/6085/2007) were assessed and compared to previous challenge studies using ALVAC‐EIV at conventional intervaccination intervals. Methods: Fourteen Thoroughbred horses and 2 ponies from a rural racehorse training property in Victoria, Australia, were vaccinated with ALVAC‐EIV on Days 0, 14 and 105. Serial blood samples were collected over the next 32 weeks and tested with haemagglutination inhibition and single radial haemolysis (SRH) in full assays to evaluate the serological response. Results: All horses and ponies responded to the accelerated ALVAC‐EIV vaccination schedule. Mean SRH antibodies remained above those consistent with clinical protection for the duration of the study period. All vaccinates demonstrated high SRH antibodies 14 days following V2, thereby achieving 100% herd immunity to homologous viral challenge. Conclusions: An accelerated vaccination schedule conferred long‐lasting protective antibody levels despite a >50% reduction in the recommended V1–V2 interval. Potential relevance: High levels of rapidly acquired herd immunity are critical in containing an outbreak of such a highly contagious pathogen as EIV. In a strategic vaccination programme, it is important that horses remain protected for sufficient time to allow control programmes to succeed. An accelerated 14 day primary course intervaccination interval and booster at 105 days achieves both of these objectives.
doi_str_mv 10.1111/j.2042-3306.2012.00605.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1283726939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2880048431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4845-53bdf9f40f843bdcc657d42e240ccd654304bf70b36c7724523a536e8db52b273</originalsourceid><addsrcrecordid>eNqNkctu1DAYhS0EokPLKyBLbNhkcHzJRWJTRqVcqiL1AhIby7H_qB4Sexo7YYanx-mUWbDCG3-Sv2P_1kEI52SZp_V2vaSE04wxUiTK6ZKQgojl9glaHA6eokVCkeUF50foRQhrQhijnD5HR5TWnOU1W6DpVGvoYFARDJ6U1tapaL3DQd-BGTvAm8FP1kCYIYKOdgLcwQRdwL7FykXbeLNLYLD2_aaDCPgOBoNt34_Oxh2OHsP9aB1g69puBPdbnaBnreoCvHzcj9Hth7Ob1cfs4uv5p9XpRaZ5xUUmWGPauuWkrXhCrQtRGk6BcqK1KQRnhDdtSRpW6LKkXFCmBCugMo2gDS3ZMXqzvzcNfz9CiLK3IX24Uw78GGROK1bSomZ1Ul__o679OLg03YNFBS05T1a1t_TgQxiglZvB9mrYyZzIuRu5lnMFcq5Azt3Ih27kNkVfPT4wNj2YQ_BvGUl4txd-2Q52_32xPPv2OUGKZ_u4DRG2h7gafsqiZKWQ3y_P5fX7H1dfLvMruWJ_AL-vrUE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1283252744</pqid></control><display><type>article</type><title>Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>EL-HAGE, C. M. ; SAVAGE, C. J. ; MINKE, J. M. ; FICORILLI, N. P. ; WATSON, J. ; GILKERSON, J. R.</creator><creatorcontrib>EL-HAGE, C. M. ; SAVAGE, C. J. ; MINKE, J. M. ; FICORILLI, N. P. ; WATSON, J. ; GILKERSON, J. R.</creatorcontrib><description>Summary Reasons for performing study: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data. This study determined the level and duration of humoral immunity following administration of a recombinant canarypox‐vectored vaccine (ALVAC‐EIV) with a primary intervaccination interval of 14 days and booster at 105 days. Objectives: To examine whether protective levels of immunity of adequate duration were achieved following a primary course reduced from a minimum interval of 28 to 14 days. Antibody responses to 2 H3N8 American lineage virus strains (including A/equine/Sydney/6085/2007) were assessed and compared to previous challenge studies using ALVAC‐EIV at conventional intervaccination intervals. Methods: Fourteen Thoroughbred horses and 2 ponies from a rural racehorse training property in Victoria, Australia, were vaccinated with ALVAC‐EIV on Days 0, 14 and 105. Serial blood samples were collected over the next 32 weeks and tested with haemagglutination inhibition and single radial haemolysis (SRH) in full assays to evaluate the serological response. Results: All horses and ponies responded to the accelerated ALVAC‐EIV vaccination schedule. Mean SRH antibodies remained above those consistent with clinical protection for the duration of the study period. All vaccinates demonstrated high SRH antibodies 14 days following V2, thereby achieving 100% herd immunity to homologous viral challenge. Conclusions: An accelerated vaccination schedule conferred long‐lasting protective antibody levels despite a &gt;50% reduction in the recommended V1–V2 interval. Potential relevance: High levels of rapidly acquired herd immunity are critical in containing an outbreak of such a highly contagious pathogen as EIV. In a strategic vaccination programme, it is important that horses remain protected for sufficient time to allow control programmes to succeed. An accelerated 14 day primary course intervaccination interval and booster at 105 days achieves both of these objectives.</description><identifier>ISSN: 0425-1644</identifier><identifier>EISSN: 2042-3306</identifier><identifier>DOI: 10.1111/j.2042-3306.2012.00605.x</identifier><identifier>PMID: 22943193</identifier><identifier>CODEN: EQVJAI</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>accelerated schedule ; ALVAC ; Animals ; Antibodies, Viral - blood ; equine influenza ; horse ; Horse Diseases - prevention &amp; control ; Horses ; Immunization Schedule ; Influenza ; Influenza Vaccines - administration &amp; dosage ; Influenza Vaccines - immunology ; Medical research ; Orthomyxoviridae Infections - prevention &amp; control ; Orthomyxoviridae Infections - veterinary ; recombinant canarypox-vectored virus ; Vaccination ; Vaccines</subject><ispartof>Equine veterinary journal, 2013-03, Vol.45 (2), p.235-239</ispartof><rights>2012 EVJ Ltd</rights><rights>2012 EVJ Ltd.</rights><rights>2013 EVJ Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4845-53bdf9f40f843bdcc657d42e240ccd654304bf70b36c7724523a536e8db52b273</citedby><cites>FETCH-LOGICAL-c4845-53bdf9f40f843bdcc657d42e240ccd654304bf70b36c7724523a536e8db52b273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.2042-3306.2012.00605.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.2042-3306.2012.00605.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22943193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>EL-HAGE, C. M.</creatorcontrib><creatorcontrib>SAVAGE, C. J.</creatorcontrib><creatorcontrib>MINKE, J. M.</creatorcontrib><creatorcontrib>FICORILLI, N. P.</creatorcontrib><creatorcontrib>WATSON, J.</creatorcontrib><creatorcontrib>GILKERSON, J. R.</creatorcontrib><title>Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza</title><title>Equine veterinary journal</title><addtitle>Equine Vet J</addtitle><description>Summary Reasons for performing study: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data. This study determined the level and duration of humoral immunity following administration of a recombinant canarypox‐vectored vaccine (ALVAC‐EIV) with a primary intervaccination interval of 14 days and booster at 105 days. Objectives: To examine whether protective levels of immunity of adequate duration were achieved following a primary course reduced from a minimum interval of 28 to 14 days. Antibody responses to 2 H3N8 American lineage virus strains (including A/equine/Sydney/6085/2007) were assessed and compared to previous challenge studies using ALVAC‐EIV at conventional intervaccination intervals. Methods: Fourteen Thoroughbred horses and 2 ponies from a rural racehorse training property in Victoria, Australia, were vaccinated with ALVAC‐EIV on Days 0, 14 and 105. Serial blood samples were collected over the next 32 weeks and tested with haemagglutination inhibition and single radial haemolysis (SRH) in full assays to evaluate the serological response. Results: All horses and ponies responded to the accelerated ALVAC‐EIV vaccination schedule. Mean SRH antibodies remained above those consistent with clinical protection for the duration of the study period. All vaccinates demonstrated high SRH antibodies 14 days following V2, thereby achieving 100% herd immunity to homologous viral challenge. Conclusions: An accelerated vaccination schedule conferred long‐lasting protective antibody levels despite a &gt;50% reduction in the recommended V1–V2 interval. Potential relevance: High levels of rapidly acquired herd immunity are critical in containing an outbreak of such a highly contagious pathogen as EIV. In a strategic vaccination programme, it is important that horses remain protected for sufficient time to allow control programmes to succeed. An accelerated 14 day primary course intervaccination interval and booster at 105 days achieves both of these objectives.</description><subject>accelerated schedule</subject><subject>ALVAC</subject><subject>Animals</subject><subject>Antibodies, Viral - blood</subject><subject>equine influenza</subject><subject>horse</subject><subject>Horse Diseases - prevention &amp; control</subject><subject>Horses</subject><subject>Immunization Schedule</subject><subject>Influenza</subject><subject>Influenza Vaccines - administration &amp; dosage</subject><subject>Influenza Vaccines - immunology</subject><subject>Medical research</subject><subject>Orthomyxoviridae Infections - prevention &amp; control</subject><subject>Orthomyxoviridae Infections - veterinary</subject><subject>recombinant canarypox-vectored virus</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>0425-1644</issn><issn>2042-3306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctu1DAYhS0EokPLKyBLbNhkcHzJRWJTRqVcqiL1AhIby7H_qB4Sexo7YYanx-mUWbDCG3-Sv2P_1kEI52SZp_V2vaSE04wxUiTK6ZKQgojl9glaHA6eokVCkeUF50foRQhrQhijnD5HR5TWnOU1W6DpVGvoYFARDJ6U1tapaL3DQd-BGTvAm8FP1kCYIYKOdgLcwQRdwL7FykXbeLNLYLD2_aaDCPgOBoNt34_Oxh2OHsP9aB1g69puBPdbnaBnreoCvHzcj9Hth7Ob1cfs4uv5p9XpRaZ5xUUmWGPauuWkrXhCrQtRGk6BcqK1KQRnhDdtSRpW6LKkXFCmBCugMo2gDS3ZMXqzvzcNfz9CiLK3IX24Uw78GGROK1bSomZ1Ul__o679OLg03YNFBS05T1a1t_TgQxiglZvB9mrYyZzIuRu5lnMFcq5Azt3Ih27kNkVfPT4wNj2YQ_BvGUl4txd-2Q52_32xPPv2OUGKZ_u4DRG2h7gafsqiZKWQ3y_P5fX7H1dfLvMruWJ_AL-vrUE</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>EL-HAGE, C. M.</creator><creator>SAVAGE, C. J.</creator><creator>MINKE, J. M.</creator><creator>FICORILLI, N. P.</creator><creator>WATSON, J.</creator><creator>GILKERSON, J. R.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza</title><author>EL-HAGE, C. M. ; SAVAGE, C. J. ; MINKE, J. M. ; FICORILLI, N. P. ; WATSON, J. ; GILKERSON, J. R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4845-53bdf9f40f843bdcc657d42e240ccd654304bf70b36c7724523a536e8db52b273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>accelerated schedule</topic><topic>ALVAC</topic><topic>Animals</topic><topic>Antibodies, Viral - blood</topic><topic>equine influenza</topic><topic>horse</topic><topic>Horse Diseases - prevention &amp; control</topic><topic>Horses</topic><topic>Immunization Schedule</topic><topic>Influenza</topic><topic>Influenza Vaccines - administration &amp; dosage</topic><topic>Influenza Vaccines - immunology</topic><topic>Medical research</topic><topic>Orthomyxoviridae Infections - prevention &amp; control</topic><topic>Orthomyxoviridae Infections - veterinary</topic><topic>recombinant canarypox-vectored virus</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>EL-HAGE, C. M.</creatorcontrib><creatorcontrib>SAVAGE, C. J.</creatorcontrib><creatorcontrib>MINKE, J. M.</creatorcontrib><creatorcontrib>FICORILLI, N. P.</creatorcontrib><creatorcontrib>WATSON, J.</creatorcontrib><creatorcontrib>GILKERSON, J. R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Equine veterinary journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>EL-HAGE, C. M.</au><au>SAVAGE, C. J.</au><au>MINKE, J. M.</au><au>FICORILLI, N. P.</au><au>WATSON, J.</au><au>GILKERSON, J. R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza</atitle><jtitle>Equine veterinary journal</jtitle><addtitle>Equine Vet J</addtitle><date>2013-03</date><risdate>2013</risdate><volume>45</volume><issue>2</issue><spage>235</spage><epage>239</epage><pages>235-239</pages><issn>0425-1644</issn><eissn>2042-3306</eissn><coden>EQVJAI</coden><abstract>Summary Reasons for performing study: During the 2007 Australian equine influenza (EI) outbreak, an accelerated primary course 14 day intervaccination schedule was proposed, but not widely implemented. Expert opinion was divided as to the efficacy of such a schedule given the lack of published data. This study determined the level and duration of humoral immunity following administration of a recombinant canarypox‐vectored vaccine (ALVAC‐EIV) with a primary intervaccination interval of 14 days and booster at 105 days. Objectives: To examine whether protective levels of immunity of adequate duration were achieved following a primary course reduced from a minimum interval of 28 to 14 days. Antibody responses to 2 H3N8 American lineage virus strains (including A/equine/Sydney/6085/2007) were assessed and compared to previous challenge studies using ALVAC‐EIV at conventional intervaccination intervals. Methods: Fourteen Thoroughbred horses and 2 ponies from a rural racehorse training property in Victoria, Australia, were vaccinated with ALVAC‐EIV on Days 0, 14 and 105. Serial blood samples were collected over the next 32 weeks and tested with haemagglutination inhibition and single radial haemolysis (SRH) in full assays to evaluate the serological response. Results: All horses and ponies responded to the accelerated ALVAC‐EIV vaccination schedule. Mean SRH antibodies remained above those consistent with clinical protection for the duration of the study period. All vaccinates demonstrated high SRH antibodies 14 days following V2, thereby achieving 100% herd immunity to homologous viral challenge. Conclusions: An accelerated vaccination schedule conferred long‐lasting protective antibody levels despite a &gt;50% reduction in the recommended V1–V2 interval. Potential relevance: High levels of rapidly acquired herd immunity are critical in containing an outbreak of such a highly contagious pathogen as EIV. In a strategic vaccination programme, it is important that horses remain protected for sufficient time to allow control programmes to succeed. An accelerated 14 day primary course intervaccination interval and booster at 105 days achieves both of these objectives.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22943193</pmid><doi>10.1111/j.2042-3306.2012.00605.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0425-1644
ispartof Equine veterinary journal, 2013-03, Vol.45 (2), p.235-239
issn 0425-1644
2042-3306
language eng
recordid cdi_proquest_miscellaneous_1283726939
source MEDLINE; Wiley Online Library All Journals
subjects accelerated schedule
ALVAC
Animals
Antibodies, Viral - blood
equine influenza
horse
Horse Diseases - prevention & control
Horses
Immunization Schedule
Influenza
Influenza Vaccines - administration & dosage
Influenza Vaccines - immunology
Medical research
Orthomyxoviridae Infections - prevention & control
Orthomyxoviridae Infections - veterinary
recombinant canarypox-vectored virus
Vaccination
Vaccines
title Accelerated vaccination schedule provides protective levels of antibody and complete herd immunity to equine influenza
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T03%3A54%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accelerated%20vaccination%20schedule%20provides%20protective%20levels%20of%20antibody%20and%20complete%20herd%20immunity%20to%20equine%20influenza&rft.jtitle=Equine%20veterinary%20journal&rft.au=EL-HAGE,%20C.%20M.&rft.date=2013-03&rft.volume=45&rft.issue=2&rft.spage=235&rft.epage=239&rft.pages=235-239&rft.issn=0425-1644&rft.eissn=2042-3306&rft.coden=EQVJAI&rft_id=info:doi/10.1111/j.2042-3306.2012.00605.x&rft_dat=%3Cproquest_cross%3E2880048431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1283252744&rft_id=info:pmid/22943193&rfr_iscdi=true